2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs

1. A compound of formula (I)

wherein:

R 1 is halogen, cyano, C(═O)OH, C(═O)OR a , C(═O)NH 2 , C(═O)N(H)R a , C(═O)N(R a )R b , C(═O)R d , hydroxyl or C 1 -C 6 -alkyl, wherein the C 1 -C 6 -alkyl radical can optionally be mono- or polysubstituted identically or differently by

hydroxyl, halogen, cyano, C(═O)OH, C(═O)OR a , S(═O) 2 —C 1 -C 6 -alkyl, NH 2 , NHR a , N(R a )R b , an optionally mono- to hexa-fluorine-substituted C 1 -C 6 -alkoxy or C 3 -C 7 -cycloalkoxy, a 4- to 7-membered heterocycloalkyl optionally mono- to trisubstituted identically or differently by R c ,

 or is C 1 -C 6 -alkoxy, where the C 1 -C 6 -alkoxy radical may optionally be mono- or polysubstituted identically or differently by

hydroxyl, halogen, cyano, C(═O)OH, C(═O)OR a , S(═O) 2 —C 1 -C 6 -alkyl, NH 2 , NHR a , N(R a )R b , an optionally mono- to tetra-fluorine-substituted C 3 -C 7 -cycloalkyl, an optionally mono- to penta-fluorine- substituted C 1 -C 6 -alkoxy, an optionally mono- to tetra-fluorine-substituted C 3 -C 7 -cycloalkoxy, a 4- to 7-membered heterocycloalkyl optionally mono- or polysubstituted identically or differently by R c ,

 or is C 3 -C 7 -cycloalkyloxy or 4- to 7-membered heterocycloalkyloxy wherein C 3 -C 7 -cycloalkyloxy and 4- to 7-membered heterocycloalkyloxy may optionally be mono- or polysubstituted identically or differently by hydroxyl, fluorine, cyano, C 1 -C 6 -alkyl or C 1 -C 6 -alkoxy;

R a is C 1 -C 6 -alkyl, C 3 -C 7 -cycloalkyl, or 4- to 7-membered heterocycloalkyl,

wherein C 1 -C 6 -alkyl, C 3 -C 7 -cycloalkyl and 4- to 7-membered heterocycloalkyl are optionally mono- or polysubstituted identically or differently by fluorine, hydroxyl, cyano, C 1 -C 4 -alkyl, C 1 -C 4 -alkoxy or C 3 -C 7 -cycloalkyl;

R b is C 1 -C 6 -alkyl or C 3 -C 7 -cycloalkyl;

or

R a and R b together with the nitrogen atom to which they are bonded form a 5- or 6-membered heterocycle which may optionally be mono- or disubstituted identically or differently by hydroxyl, halogen, cyano, or C 1 -C 6 -alkyl;

R c is hydroxyl, fluorine, chlorine, cyano, C 1 -C 4 -alkyl or C 1 -C 4 -alkoxy;

R d is hydrogen, C 3 -C 7 -cycloalkyl, or C 1 -C 6 -alkyl which may optionally be substituted by a hydroxyl group;

R 2 is 5-membered heteroaryl which may be monosubstituted by R 4 and monosubstituted by R 5 ; or

R 2 is 6-membered heteroaryl which may be monosubstituted by R 4 and mono- or disubstituted identically or differently by R 5 ;

R 3 is a group selected from:

 where * represents the bonding site of the group to the rest of the molecule;

R 4 is hydrogen, halogen, hydroxyl, C(═O)OH, cyano, NH 2 , NHR a , N(R a )R b , C(═O)R a , N(H)C(═O)R a , C(═O)NH 2 , C(═O)N(H)R a , C(═O)N(R a )R b , S(═O)R a , S(═O) 2 R a , S(═O) 2 NH 2 , S(═O) 2 NHR a or S(═O) 2 N(R a )R b ,

 or is C 1 -C 6 -alkyl, where C 1 -C 6 -alkyl may optionally be substituted by one to five fluorine atoms and may optionally be mono- or disubstituted identically or differently by hydroxyl, bromine, chlorine, cyano, C(═O)OH, S(═O) 2 —C 1 -C 6 -alkyl, NH 2 , NHR a , N(R a )R b , C 3 -C 7 -cycloalkyl, C 1 -C 4 -alkoxy, C 3 -C 7 -cycloalkoxy, trifluoromethoxy,

 or is C 1 -C 6 -alkoxy, where C 1 -C 6 -alkoxy may optionally be substituted by one to five fluorine atoms and may optionally be mono- or disubstituted identically or differently by hydroxyl, chlorine, bromine, cyano, C(═O)OH, S(═O) 2 —C 1 -C 6 -alkyl, NH 2 , NHR a , N(R a )R b , C 3 -C 7 -cycloalkyl, C 1 -C 4 -alkoxy, C 3 -C 7 -cycloalkoxy, trifluoromethoxy,

 or is C 3 -C 7 -cycloalkyl or is C 3 -C 7 -cycloalkyloxy, where C 3 -C 7 -cycloalkyl and C 3 -C 7 -cycloalkyloxy may optionally be substituted by one to four fluorine atoms and may optionally be mono- or disubstituted identically or differently by hydroxyl, chlorine, bromine, cyano, C(═O)R d , C(═O)OH, C 1 -C 6 -alkyl or C 1 -C 4 -alkoxy,

 or is 4-7-membered heterocycloalkyl which may optionally be substituted by one to four fluorine atoms and may optionally be mono- or disubstituted identically or differently by hydroxyl, chlorine, bromine, cyano, NH 2 , NHR a , N(R a )R b , C(═O)R d , C(═O)OH, C 1 -C 6 -alkyl, trifluoromethyl, 2,2,2-trifluoroethyl, cyclopropyl, cyclopropylmethyl or C 1 -C 4 -alkoxy,

 or is phenyl or 5- or 6-membered heteroaryl, wherein said phenyl and 5- or 6-membered heteroaryl may optionally be mono- to disubstituted identically or differently by fluorine, chlorine, bromine, hydroxyl, cyano, C(═O)OH, S(═O) 2 —C 1 -C 4 -alkyl, NH 2 , NHR a , N(R a )R b , N(H)C(═O)R a , C 1 -C 4 -alkoxy, trifluoromethoxy or C 1 -C 4 -alkyl, where C 1 -C 4 -alkyl may optionally be mono- to trisubstituted by fluorine;

R 5 is hydrogen, halogen, hydroxyl, cyano, C 1 -C 4 -alkoxy, trifluoromethoxy or C 1 -C 6 -alkyl, wherein C 1 -C 6 -alkyl may optionally be substituted by one to five fluorine atoms,

R 6f is hydrogen, fluorine, C(═O)OH, C(═O)NH 2 , trifluoromethyl, hydroxymethyl, methoxymethyl, cyano or C 1 -C 6 -alkyl,

R 6g is hydrogen, fluorine or C 1 -C 6 -alkyl; or

R 6f and R 6g together with the carbon atom to which they are bonded form a C 3 -C 7 -cycloalkyl; or

R 6f and R 6g together are an oxo group;

R 6h is hydrogen, trifluoromethyl or C 1 -C 6 -alkyl; and

R 6i is hydrogen or C 1 -C 6 -alkyl; or

R 6h and R 6i together are an oxo group,

R 6j is hydrogen, fluorine, NH 2 , N(H)R a , N(R a )R b , C 1 -C 6 -alkyl, hydroxyl, cyano, C 1 -C 4 -alkoxy, C(═O)OH, C(═O)NH 2 , C(═O)N(H)R a , C(═O)N(R a )R b , hydroxymethyl, dimethylaminomethyl, or trifluoromethyl,

R 6k is hydrogen, fluorine or C 1 -C 6 -alkyl; or

R 6j and R 6k together with the carbon atom to which they are bonded form a C 3 -C 7 -cycloalkyl,

R 6l is hydrogen or methyl,

R 6m is hydrogen or methyl,

G is —CH 2 — or —CH 2 CH 2 —,

n in the formula R 3a is 0, 1 or 2,

n in the formula R 3b is 1 or 2,

n in the formula R 3c is 0 or 1,

z is a group selected from the group consisting of NR 7 , O, S, S(═O), S(═O) 2 , and S(═O)(═NH);

R 7 is hydrogen, C(═O)R e , C(═O)OR a , C(═O)NH 2 , C(═O)N(H)R a , C(═O)N(R a )R b , S(═O) 2 R a , S(═O) 2 NH 2 , S(═O) 2 N(R a )H, S(═O) 2 N(R a )R b , S(═O) 2 NHC(═O)CH 3 , S(═O) 2 NHC(═O)CH 2 CH 3 or C 1 -C 6 -alkyl, wherein

C 1 -C 6 -alkyl may optionally be mono- to pentasubstituted by fluorine atoms and mono- to disubstituted identically or differently by hydroxyl, chlorine, bromine, cyano, C(═O)R a , C(═O)OH, C(═O)NH 2 , C(═O)N(H)R a , C(═O)N(R a )R b , S(═O) 2 —C 1 -C 6 -alkyl, NH 2 , NHR a , N(R a )R b , morpholin-4-yl, 4-methylpiperazin-1-yl, C 3 -C 7 -cycloalkyl, C 1 -C 4 -alkoxy or C 3 -C 7 -cycloalkoxy,

 or is C 3 -C 7 -cycloalkyl which may optionally be mono- to tetrasubstituted by fluorine atoms and may optionally be mono- to disubstituted identically or differently by hydroxyl, methyl, ethyl, trifluoromethyl or cyano,

 or is a 4-7-membered heterocycloalkyl bonded to the rest of the molecule by a carbon atom or is 4-7-membered heterocycloalkyl-C 1 -C 4 -alkyl which may optionally be mono-to hexasubstituted by fluorine atoms and mono- to trisubstituted identically or differently by hydroxyl, chlorine, bromine, cyano, C 1 -C 6 -alkyl, C 1 -C 6 -alkoxy, trifluoromethyl, 2,2,2-trifluoroethyl, trifluoromethoxy, cyclopropyl, or cyclopropylmethyl,

R e is C 1 -C 6 -alkyl, where C 1 -C 6 -alkyl may optionally be mono- to trisubstituted identically or differently by hydroxyl, fluorine, chlorine, cyano, C(═O)R a , C(═O)OH, NH 2 , NHR a , N(R a )R b , C 3 -C 7 -cycloalkyl, C 1 -C 4 -alkoxy, trifluoromethoxy or C 3 -C 7 -cycloalkoxy; or

R e is C 3 -C 7 -cycloalkyl, where C 3 -C 7 -cycloalkyl may optionally be mono- to tetrasubstituted by fluorine and may optionally be monosubstituted by hydroxyl,

or a diastereomer, an enantiomer, a metabolite, a salt, a solvate, or a solvate of a salt thereof.

2. The compound according to claim 1 , or a diastereomer, an enantiomer, a metabolite, a salt, a solvate, or a solvate of a salt thereof, wherein R 1 is hydroxymethyl, 1-hydroxyethyl or 2-hydroxypropan-2-yl.

3. The compound according to claim 1 , or a diastereomer, an enantiomer, a metabolite, a salt, a solvate, or a solvate of a salt thereof, wherein

R 2 is a pyridin-2-yl radical substituted at the 6 position by C 1 -C 6 -alkyl, where C 1 -C 6 -alkyl is optionally substituted by up to 5 fluorine atoms; or

R 2 is a pyridin-2-yl radical substituted at the 6 position by cyano, chlorine, cyclopropyl, cyclopropylmethyl, NH 2 , NH(C 1 -C 4 -alkyl), N(C 1 -C 4 -alkyl) 2 , C 1 -C 4 -alkoxy, 2,2,2-trifluoroethoxy, 2-hydroxypropan-2-yl, morpholin-4-yl, 4-methylpiperazin-1-yl or piperazin-1-yl.

4. The compound according to claim 3 , or a diastereomer, an enantiomer, a metabolite, a salt, a solvate, or a solvate of a salt thereof, wherein

R 2 is a pyridin-2-yl radical substituted at the 6 position by trifluoromethyl, difluoromethyl, methyl, 2,2,2-trifluoroethyl, 1,1-difluoroethyl, ethyl, isopropyl, tert-butyl, cyano, chlorine, cyclopropyl, cyclopropylmethyl, NH 2 , NH(C 1 -C 4 -alkyl), N(C 1 -C 4 -alkyl) 2 , C 1 -C 4 -alkoxy, 2,2,2-trifluoroethoxy, 2-hydroxypropan-2-yl, morpholin-4-yl, 4-methylpiperazin-1-yl or piperazin-1-yl.

5. The compound according to claim 4 , or a diastereomer, an enantiomer, a metabolite, a salt, a solvate, or a solvate of a salt thereof, wherein

R 2 is 6-(trifluoromethyl)pyridin-2-yl, 6-(difluoromethyl)pyridin-2-yl, 6-(1,1-difluoroethyl)pyridin-2-yl, 6-aminopyridin-2-yl or 6-(2-hydroxypropan-2-yl)pyridin 2-yl.

6. The compound according to claim 1 , or a diastereomer, an enantiomer, a metabolite, a salt, a solvate, or a solvate of a salt thereof, wherein

R 1 is C(═O)NH 2 , 2-hydroxypropan-2-yl or methoxy;

R 2 is 6-(trifluoromethyl)pyridin-2-yl, 6-(difluoromethyl)pyridin-2-yl, 6-aminopyridin-2-yl, 4-(trifluoromethyl)-1,3-thiazol-2-yl, or 1-(difluoromethyl)-1H-pyrazol-3-yl; and

R 3 is tetrahydro-2H-pyran-4-yl, 1,1-dioxidotetrahydro-2H-thiopyran-4-yl, tetrahydrofuran-3-yl, (3S)-tetrahydrofuran-3-yl, (3R)-tetrahydrofuran-3-yl or (3S)-1,1-dioxidotetrahydrothiophen-3-yl; or

R 3 is piperidin-4-yl, 1-(2,2,2-trifluoroethyl)piperidin-4-yl, 1-methylpiperidin-4-yl, 1-glycoloylpiperidin-4-yl, 1′-methyl-1,4′-bipiperidin-4-yl, 1-(acetylsulphamoyl)piperidin-4-yl, [2-(dimethylamino)ethyl]piperidin-4-yl, 1-(oxetan-3-yl)piperidin-4-yl, 1-(2-hydroxyethyl)piperidin-4-yl or 1-(3-hydroxy-3-methylbutyl)piperidin-4-yl.

7. The compound according to claim 1 , wherein the compound is selected from the group consisting of:

(1) N-[6-methoxy-2-(tetrahydro-2H-pyran-4-yl)-2H-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide;

(2) N-[6-methoxy-2-(piperidin-4-yl)-2H-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide;

(3) N-{6-methoxy-2-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]-2H-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide;

(4) N-[6-methoxy-2-(1-methylpiperidin-4-yl)-2H-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide;

(5) N-[2-(1-glycoloylpiperidin-4-yl)-6-methoxy-2H-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide;

(6) N-[6-methoxy-2-(1′-methyl-1,4′-bipiperidin-4-yl)-2H-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide;

(7) N-[6-methoxy-2-(1-sulphamoylpiperidin-4-yl)-2H-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide;

(8) N-{2-[1-(acetylsulphamoyl)piperidin-4-yl]-6-methoxy-2H-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide;

(9) N-(2-{1-[2-(dimethylamino)ethyl]piperidin-4-yl}-6-methoxy-2H-indazol-5-yl)-6-(trifluoromethyl)pyridine-2-carboxamide;

(10) N-{6-methoxy-2-[1-(oxetan-3-yl)piperidin-4-yl]-2H-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide;

(11) N-[2-(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-6-methoxy-2H-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide;

(12) N-[6-methoxy-2-(1-oxidotetrahydro-2H-thiopyran-4-yl)-2H-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide;

(13) N-{2-[1-(2-hydroxyethyl)piperidin-4-yl]-6-methoxy-2H-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide;

(14) rel-N-{2-[(1R,4R,5S)-2-azabicyclo[2.2.1]hept-5-yl]-6-methoxy-2H-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide;

(15) rel-N-{2-[(1R,4R,5R)-2-azabicyclo[2.2.1]hept-5-yl]-6-methoxy-2H-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide;

(16) N-[2-(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-6-hydroxy-2H-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide;

(17) N-[6-(cyclopropylmethoxy)-2-(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-2H-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide;

(18) rel-N-{6-methoxy-2-[(1R,4R,5S)-2-methyl-2-azabicyclo[2.2.1]hept-5-yl]-2H-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide;

(19) rel-N-{6-methoxy-2-[(1R,4R,5R)-2-methyl-2-azabicyclo[2.2.1]hept-5-yl]-2H-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide;

(20) N-[2-(1-imino-1-oxidohexahydro-1λ 4 -thiopyran-4-yl)-6-methoxy-2H-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide (isomer 1);

(21) N-[2-(1-imino-1-oxidohexahydro-1λ 4 -thiopyran-4-yl)-6-methoxy-2H-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide (isomer 2);

(22) N-[6-methoxy-2-(5-oxopyrrolidin-3-yl)-2H-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide;

(23) 6-(difluoromethyl)-N-[6-methoxy-2-(tetrahydro-2H-pyran-4-yl)-2H-indazol-5-yl]pyridine-2-carboxamide;

(24) N-[6-methoxy-2-(tetrahydro-2H-pyran-4-yl)-2H-indazol-5-yl]-6-(morpholin-4-yl)pyridine-2-carboxamide;

(25) N-[6-methoxy-2-(tetrahydro-2H-pyran-4-yl)-2H-indazol-5-yl]-2-methyl-1,3-thiazole-4-carboxamide;

(26) 6-amino-N-[6-methoxy-2-(tetrahydro-2H-pyran-4-yl)-2H-indazol-5-yl]pyridine-2-carboxamide;

(27) 2-isopropyl-N-[6-methoxy-2-(tetrahydro-2H-pyran-4-yl)-2H-indazol-5-yl]pyrimidine-4-carboxamide;

(28) 6-(2-hydroxypropan-2-yl)-N-[6-methoxy-2-(tetrahydro-2H-pyran-4-yl)-2H-indazol-5-yl]pyridine-2-carboxamide;

(29) N-[6-methoxy-2-(tetrahydrofuran-3-yl)-2H-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide;

(30) N-[6-chloro-2-(tetrahydro-2H-pyran-4-yl)-2H-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide;

(31) N-[6-chloro-2-(tetrahydro-2H-pyran-4-yl)-2H-indazol-5-yl]-6-(difluoromethyl)pyridine-2-carboxamide;

(32) N-[6-chloro-2-(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-2H-indazol-5-yl]-6-(2-hydroxypropan-2-yl)pyridine-2-carboxamide;

(33) methyl 2-(tetrahydro-2H-pyran-4-yl)-5-({[6-(trifluoromethyl)pyridin-2-yl]carbonyl}amino)-2H-indazole-6-carboxylate;

(34) N-[6-(2-hydroxypropan-2-yl)-2-(tetrahydro-2H-pyran-4-yl)-2H-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide;

(35) methyl 2-[(3S)-tetrahydrofuran-3-yl]-5-({[6-(trifluoromethyl)pyridin-2-yl]carbonyl}amino)-2H-indazole-6-carboxylate;

(36) N-{6-(2-hydroxypropan-2-yl)-2-[(3S)-tetrahydrofuran-3-yl]-2H-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide;

(37) methyl 2-[(3R)-tetrahydrofuran-3-yl]-5-({[6-(trifluoromethyl)pyridin-2-yl]carbonyl}amino)-2H-indazole-6-carboxylate;

(38) N-{6-(2-hydroxypropan-2-yl)-2-[(3R)-tetrahydrofuran-3-yl]-2H-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide;

(39) methyl 2-[(3S)-tetrahydrothiophen-3-yl]-5-({[6-(trifluoromethyl)pyridin-2-yl]carbonyl}amino)-2H-indazole-6-carboxylate;

(40) N-{6-(2-hydroxypropan-2-yl)-2-[(3S)-tetrahydrothiophen-3-yl]-2H-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide;

(41) N-{2-[(3S)-1,1-dioxidotetrahydrothiophen-3-yl]-6-(2-hydroxypropan-2-yl)-2H-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide;

(42) methyl 2-(tetrahydro-2H-thiopyran-4-yl)-5-({[6-(trifluoromethyl)pyridin-2-yl]carbonyl}amino)-2H-indazole-6-carboxylate;

(43) N-[6-(2-hydroxypropan-2-yl)-2-(tetrahydro-2H-thiopyran-4-yl)-2H-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide;

(44) N-[2-(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-6-(2-hydroxypropan-2-yl)-2H-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide;

(45) methyl 2-(piperidin-4-yl)-5-({[6-(trifluoromethyl)pyridin-2-yl]carbonyl}amino)-2H-indazole-6-carboxylate;

(46) N-[6-(2-hydroxypropan-2-yl)-2-(piperidin-4-yl)-2H-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide;

(47) N-[6-methoxy-2-(tetrahydro-2H-pyran-4-yl)-2H-indazol-5-yl]-4-(trifluoromethyl)-1,3-thiazole-2-carboxamide;

(48) N-[6-methoxy-2-(tetrahydro-2H-pyran-4-yl)-2H-indazol-5-yl]-3-(pyridin-4-yl)-1,2,4-oxadiazole-5-carboxamide;

(49) N-[6-methoxy-2-(tetrahydro-2H-pyran-4-yl)-2H-indazol-5-yl]-3-methyl-1,2,4-oxadiazole-5-carboxamide;

(50) N-[6-chloro-2-(tetrahydro-2H-pyran-4-yl)-2H-indazol-5-yl]-4-(trifluoromethyl)-1,3-thiazole-2-carboxamide;

(51) 1-(difluoromethyl)-N-[6-methoxy-2-(tetrahydro-2H-pyran-4-yl)-2H-indazol-5-yl]-1H-pyrazole-3-carboxamide;

(52) N-{2-[1-(3-hydroxy-3-methylbutyl)piperidin-4-yl]-6-methoxy-2H-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide;

(53) 2-(piperidin-4-yl)-5-({[6-(trifluoromethyl)pyridin-2-yl]carbonyl}amino)-2H-indazole-6-carboxamide;

(54) 2-(piperidin-4-yl)-5-({[6-(trifluoromethyl)pyridin-2-yl]carbonyl}amino)-2H-indazole-6-carboxylic acid;

(55) methyl 2-(1-methylpiperidin-4-yl)-5-({[6-(trifluoromethyl)pyridin-2-yl]carbonyl}amino)-2H-indazole-6-carboxylate;

(56) 2-[1-(3-hydroxy-3-methylbutyl)piperidin-4-yl]-5-({[6-(trifluoromethyl)pyridin-2-yl]carbonyl}amino)-2H-indazole-6-carboxamide;

(57) 2-(1-methylpiperidin-4-yl)-5-({[6-(trifluoromethyl)pyridin-2-yl]carbonyl}amino)-2H-indazole-6-carboxamide; and

(58) N-{6-methoxy-2-[1-(2-methoxyethyl)piperidin-4-yl]-2H-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide,

or a diastereomer, an enantiomer, a metabolite, a salt, a solvate, or a solvate of a salt thereof.

8. A pharmaceutical composition comprising a compound of formula (I) according to claim 1 in combination with an inert, non-toxic, pharmaceutically suitable excipient.